Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCS100 for Aflatoxin Exposure Reduction in Kenya
NCT02188953Phase 2Completed
- Sponsor
- Kenya Medical Research Institute
- Start
- Aug 2014
- Primary completion
- Sep 2014
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ACCS100 in aflatoxicosis, sponsored by Kenya Medical Research Institute. Started Aug 2014; status: completed.
02
Drugs
ACCS100
03
Conditions
aflatoxicosis
Beyond the preview
Go deeper on NCT02188953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02188953.